FMS vs. DVA, SHC, SWAV, RDY, PODD, RVTY, MEDP, SRPT, CRL, and INCY
Should you be buying Fresenius Medical Care stock or one of its competitors? The main competitors of Fresenius Medical Care include DaVita (DVA), Sotera Health (SHC), Shockwave Medical (SWAV), Dr. Reddy's Laboratories (RDY), Insulet (PODD), Revvity (RVTY), Medpace (MEDP), Sarepta Therapeutics (SRPT), Charles River Laboratories International (CRL), and Incyte (INCY). These companies are all part of the "medical" sector.
Fresenius Medical Care (NYSE:FMS) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.
DaVita has a net margin of 5.70% compared to Fresenius Medical Care's net margin of 2.56%. DaVita's return on equity of 64.42% beat Fresenius Medical Care's return on equity.
DaVita received 88 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 61.81% of users gave DaVita an outperform vote while only 53.94% of users gave Fresenius Medical Care an outperform vote.
DaVita has lower revenue, but higher earnings than Fresenius Medical Care. DaVita is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
Fresenius Medical Care has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
In the previous week, DaVita had 16 more articles in the media than Fresenius Medical Care. MarketBeat recorded 18 mentions for DaVita and 2 mentions for Fresenius Medical Care. Fresenius Medical Care's average media sentiment score of 1.32 beat DaVita's score of 0.69 indicating that Fresenius Medical Care is being referred to more favorably in the media.
8.3% of Fresenius Medical Care shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 1.4% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Fresenius Medical Care presently has a consensus price target of $24.00, indicating a potential upside of 10.80%. DaVita has a consensus price target of $118.50, indicating a potential downside of 16.67%. Given Fresenius Medical Care's higher probable upside, research analysts clearly believe Fresenius Medical Care is more favorable than DaVita.
Summary
DaVita beats Fresenius Medical Care on 13 of the 18 factors compared between the two stocks.
Get Fresenius Medical Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for FMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresenius Medical Care Competitors List
Related Companies and Tools
